{
  "patent_number": "US 10314897",
  "country": "US",
  "title": "How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer",
  "original_title": "Peptides and combination of peptides for use in immunotherapy against various cancers",
  "summary": "This patent describes methods to fight various cancers by using a specific protein fragment (peptide LYHDIFSRL) to train a patient's immune cells to recognize and attack tumor cells.",
  "what_it_does": "This patent describes two main ways to use a specific protein fragment, called a peptide, to fight cancer. One method (Claim 1) involves taking T cells from a patient or a donor, activating them in the lab to recognize a specific peptide called LYHDIFSRL (SEQ ID NO: 271) when it's displayed on cancer cells by an MHC molecule, and then giving these activated T cells back to the patient. These trained T cells then seek out and kill cancer cells that display this peptide. The patent lists many cancers that can be treated this way, including glioblastoma, breast cancer, and non-small cell lung cancer. The second method (Claim 19) involves directly administering a composition containing the LYHDIFSRL peptide to the patient. This peptide then teaches the patient's own immune system to create T cells that can recognize and attack the cancer cells.",
  "what_it_does_not_cover": [
    "Does not cover methods using different peptides or protein fragments other than LYHDIFSRL (SEQ ID NO: 271) to elicit an immune response against cancer.",
    "Does not cover immunotherapies for cancer types not explicitly listed in the claims, such as certain rare cancers or pediatric cancers.",
    "Does not cover general cancer treatments that do not involve T cells or the specific peptide-MHC interaction described.",
    "Does not cover preventative cancer vaccines that aim to stop cancer from forming in the first place, only treatments for existing cancer.",
    "Does not cover T-cell therapies that target cancer cells through mechanisms entirely different from recognizing a peptide presented by an MHC molecule."
  ],
  "filed": "2018-08-21",
  "granted": "2019-06-11",
  "expires": "2038-08-21",
  "status": "active",
  "holder": "Immatics Biotechnologies",
  "holder_url": "https://patentbrief.org/company/immatics-biotechnologies",
  "inventors": [
    {
      "name": "Oliver Schoor",
      "url": "https://patentbrief.org/inventor/oliver-schoor"
    },
    {
      "name": "Colette SONG",
      "url": "https://patentbrief.org/inventor/colette-song"
    },
    {
      "name": "Harpreet Singh",
      "url": "https://patentbrief.org/inventor/harpreet-singh"
    },
    {
      "name": "Andrea MAHR",
      "url": "https://patentbrief.org/inventor/andrea-mahr"
    },
    {
      "name": "Toni Weinschenk",
      "url": "https://patentbrief.org/inventor/toni-weinschenk"
    },
    {
      "name": "Jens FRITSCHE",
      "url": "https://patentbrief.org/inventor/jens-fritsche"
    }
  ],
  "times_cited": 4,
  "tags": [
    "biotech",
    "pharmaceutical",
    "immunotherapy",
    "oncology",
    "gene_editing"
  ],
  "abstract": "The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.",
  "url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca",
  "markdown_url": "https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca/md",
  "google_patents_url": "https://patents.google.com/patent/US10314897",
  "relatedPatents": [
    {
      "patentNumber": "12168044",
      "countryCode": "US",
      "title": "Treating Liver Cancer with Specially Trained Immune Cells",
      "url": "https://patentbrief.org/patent/us/12168044/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-non-small-"
    },
    {
      "patentNumber": "9328156",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Attack Cancer",
      "url": "https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer"
    },
    {
      "patentNumber": "9481728",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Fight CD19 Cancers",
      "url": "https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer"
    },
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "5455030",
      "countryCode": "US",
      "title": "How to Build Smaller, Synthetic Antibody-Like Molecules for Medicine",
      "url": "https://patentbrief.org/patent/us/5455030/immunotheraphy-using-single-chain-polypeptide-binding-molecules"
    }
  ]
}